Search Market Research Report
Atopic Eczema Treatment Market Size, Share Global Analysis Report, 2024 – 2032
Atopic Eczema Treatment Market Size, Share, Growth Analysis Report By Drug Class (Biologics, PDE-4 Inhibitors, Calcineurin Inhibitors, and Corticosteroids), By Route of Administration (Injectable, Topical, and Oral), By Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and By Region - Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2024 – 2032
Industry Insights
[211+ Pages Report] According to Facts & Factors, the global atopic eczema treatment market size in terms of revenue was valued at around USD 14.26 billion in 2023 and is expected to reach a value of USD 29.15 billion by 2032, growing at a CAGR of roughly 8.2% from 2024 to 2032. The global atopic eczema treatment market is projected to grow at a significant growth rate due to several driving factors.
Market Overview
Atopic eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition characterized by itchy, red, swollen, and cracked skin. It is a common condition that often begins in childhood but can persist into adulthood. The treatment of atopic eczema aims to manage symptoms, reduce flare-ups, and improve the quality of life for patients.
The atopic eczema treatment market encompasses various therapeutic options, including topical treatments, systemic medications, biologics, and phototherapy. The market is expanding due to increasing prevalence of the condition, advancements in treatment options, and growing awareness about the disease and its management.
Key Highlights
- The atopic eczema treatment market has registered a CAGR of 8.2% during the forecast period.
- In terms of revenue, the global atopic eczema treatment market was estimated at roughly USD 14.26 billion in 2023 and is predicted to attain a value of USD 29.15 billion by 2032.
- The atopic eczema treatment market is expanding due to rising prevalence, advancements in treatment options, and growing awareness.
- Based on the drug class, the biologics segment is growing at a high rate and is projected to dominate the global market.
- In terms of route of administration, the injectable segment is projected to swipe the largest market share.
- On the basis of application, the hospital pharmacies segment is expected to dominate the global market.
- By region, North America dominates the market due to high prevalence of the condition, advanced healthcare infrastructure, and high expenditure on healthcare.
Atopic Eczema Treatment Market: Growth Drivers
- Rising Prevalence of Atopic Eczema: Atopic eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition affecting both children and adults. The increasing prevalence of this condition globally fuels the demand for effective treatment options.
- Growing Awareness and Diagnosis: Increased awareness and improved diagnostic tools lead to earlier detection and treatment of atopic eczema, further driving market growth.
- Development of Novel Therapies: The introduction of new and more effective treatment options, such as biologics and phosphodiesterase-4 (PDE4) inhibitors, provides more choices for patients and healthcare providers.
- Increased Healthcare Spending: Rising healthcare expenditure globally allows for greater investment in new therapies and treatment approaches for atopic eczema.
Restraints:
- High Cost of Treatment: Many atopic eczema treatments, especially newer biologics, can be expensive, limiting accessibility for some patients.
- Lack of Complete Cure: Currently, there is no permanent cure for atopic eczema. Treatment focuses on managing symptoms and preventing flare-ups.
- Side Effects of Medications: Some atopic eczema medications can cause side effects, leading patients to seek alternative treatment options.
Opportunities:
- Emerging Markets: Developing economies with growing disposable incomes present a significant opportunity for the atopic eczema treatment market.
- Focus on Patient Convenience: The development of topical formulations and self-administered therapies offer greater convenience for patients managing their condition.
- Personalized Medicine: Advancements in personalized medicine allow for tailoring treatment plans to individual patient needs and genotypes.
Challenges:
- Stringent Regulatory Requirements: The strict regulatory approval process for new medications can delay the availability of innovative treatments to patients.
- Counterfeit Drugs: The presence of counterfeit drugs in some markets can undermine trust in legitimate treatment options.
- Patient Adherence: Long-term use of medications and adherence to treatment plans can be a challenge for some patients.
Atopic Eczema Treatment Market: Segmentation Analysis
The global atopic eczema treatment market is segmented based on drug class, route of administration, application, and region.
By Drug Class Insights
Based on Drug Class, the global atopic eczema treatment market is divided into biologics, PDE-4 inhibitors, calcineurin inhibitors, and corticosteroids. Biologics segment accounted for 41.6% of revenue share in 2023. Biologics are advanced drugs derived from living organisms that target specific components of the immune system to reduce inflammation and other symptoms associated with atopic eczema. These treatments are typically used for moderate to severe cases that do not respond well to traditional therapies. Biologics have shown high effectiveness in reducing symptoms and improving the quality of life for patients with severe atopic eczema. Continuous R&D efforts are leading to the development of new biologics and expanding their indications. Increasing prevalence of atopic eczema globally boosts demand for effective treatments like biologics??.
On the other hand, the PDE-4 inhibitors segment is registering substantial growth at a CAGR of 11.3% between 2024 to 2032. Phosphodiesterase-4 (PDE-4) inhibitors reduce inflammation by blocking the PDE-4 enzyme, which is involved in the inflammatory process. These are typically used for mild to moderate cases of atopic eczema. PDE-4 inhibitors provide an alternative to corticosteroids, appealing to patients and physicians seeking non-steroidal treatments. They are effective in reducing symptoms with a favorable safety profile, which enhances their acceptance. Growing awareness about the availability and benefits of PDE-4 inhibitors drives market growth?.
Calcineurin inhibitors work by suppressing the immune system to reduce inflammation and are often used for patients who do not respond well to corticosteroids or for sensitive areas where steroids are not recommended. These inhibitors provide a targeted approach to managing atopic eczema, especially in sensitive areas like the face and neck. They are an alternative for patients who need long-term treatment without the side effects associated with steroids. Increasing regulatory approvals for new formulations enhance market growth??.
Corticosteroids are anti-inflammatory medications widely used to treat various forms of atopic eczema. They are available in multiple formulations, including creams, ointments, and oral medications. Corticosteroids are effective in providing quick relief from symptoms, making them a mainstay treatment for acute flares. Their effectiveness and affordability make them widely used across different severity levels of atopic eczema. Development of new formulations with improved safety profiles continues to support their use??.
By Route of Administration Insights
On the basis of Route of Administration, the global atopic eczema treatment market is bifurcated into injectable, topical, and oral. Injectable segment dominated the global market, accounting for approximately 42.5% of the total market revenue in 2023. Injectable treatments are administered via injection, often used for moderate to severe cases of atopic eczema that do not respond well to topical or oral treatments. This category primarily includes biologics, which are designed to target specific components of the immune system. Injectable biologics provide targeted and highly effective treatment for severe atopic eczema, reducing symptoms significantly. Increasing physician and patient acceptance of biologics due to their effectiveness and relatively fewer side effects compared to traditional systemic treatments.
Topical treatments are applied directly to the skin, including creams, ointments, gels, and lotions. They are the most common form of treatment for mild to moderate atopic eczema and are often the first line of therapy. Topical treatments are easy to apply and can be used at home, making them highly convenient for patients. A broad range of topical treatments is available over the counter and by prescription, catering to different severity levels and patient needs.
Oral segment is projected to grow at the fastest rate during the forecast timeframe. Oral treatments are taken by mouth and include systemic therapies for moderate to severe atopic eczema. They are typically used when topical treatments are insufficient or for widespread disease. Oral medications provide systemic treatment, which is essential for managing severe cases that are not adequately controlled by topical treatments alone. Oral treatments can target a wide range of symptoms and provide comprehensive management of atopic eczema.
By Application Insights
Based on Application, the global atopic eczema treatment market is categorized into hospital pharmacies, retail pharmacies, online pharmacies, and others. Hospital pharmacies segment accounted for 56.2% of the total revenue share in 2023. Hospital pharmacies play a crucial role in dispensing medications for inpatients and outpatients, particularly for severe cases of atopic eczema that require specialized care and biologics. Hospital pharmacies are often involved in the management of severe atopic eczema cases that require biologics and other advanced treatments. They provide specialized care and patient education, ensuring proper medication administration and adherence?. Hospital pharmacies have access to the latest treatments and clinical trial medications, which are crucial for managing complex cases?.
Retail pharmacies are the primary point of contact for patients seeking prescription and over-the-counter medications for atopic eczema. They are widely accessible and cater to a large patient base. Retail pharmacies are easily accessible to the general public, providing convenient access to medications and counseling services??. They offer a broad range of topical and oral treatments, making them a preferred choice for managing mild to moderate atopic eczema??.
Online pharmacies offer medications through digital platforms, providing a convenient and often cost-effective option for patients. This segment has seen rapid growth, particularly during the COVID-19 pandemic. Online pharmacies provide the convenience of ordering medications from home, with home delivery services enhancing patient compliance?. They often offer competitive pricing and discounts, making treatments more affordable for patients??.
Recent Developments:
The year 2022 saw significant progress in raising awareness and expanding treatment options for atopic dermatitis (eczema).
- Leo Pharma launched a cross-cultural campaign featuring patients from France, Italy, Germany, and Spain. By sharing their stories, the campaign sheds light on the real-life challenges individuals face living with this chronic skin condition.
- Sanofi scored a major win with the U.S. FDA's approval of Dupixent (dupilumab) for treating atopic dermatitis in children as young as 6 months old. This approval broadens the reach of this effective medication, offering hope and relief to younger patients and their families.
Report Scope
Report Attribute |
Details |
Market Size in 2023 |
USD 14.26 Billion |
Projected Market Size in 2032 |
USD 29.15 Billion |
CAGR Growth Rate |
8.2% CAGR |
Base Year |
2023 |
Forecast Years |
2024-2032 |
Key Market Players |
AbbVie Inc., AnaptysBio Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Dermira Inc. (acquired by Eli Lilly and Company), Encore Dermatology Inc., Galderma S.A., Incyte Corporation, LEO Pharma A/S, Medimetriks Pharmaceuticals Inc., Medimmune LLC. (AstraZeneca), Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, and Others. |
Key Segment |
By Drug Class, By Route of Administration, By Application, and By Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East &, Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
Atopic Eczema Treatment Market: Regional Analysis
- North America dominates the global market during the forecast period
North America has captured a market share of around 43.4% in 2023. The North American atopic eczema treatment market is substantial, driven primarily by the high prevalence of atopic dermatitis and strong healthcare infrastructure. The United States dominates this market at a CAGR of 7.6%, due to its advanced healthcare system, high healthcare spending, and significant R&D activities in dermatology. The growth is fueled by increasing awareness of skin diseases, rising adoption of biologics and advanced therapies, and a growing number of clinical trials. The market benefits from the presence of major pharmaceutical companies and innovative product launches. Key players in this region include Pfizer Inc., AbbVie and Viatris.
Europe represents a mature and growing market for atopic eczema treatment. The market is driven by high awareness of skin conditions, strong healthcare infrastructure, and substantial investments in dermatological research. Countries such as Germany, France, and the UK are the key markets within the region. Germany dominates the market, owing to its advanced healthcare system and high expenditure on healthcare. The demand for atopic eczema treatments is supported by an increasing prevalence of the condition and the availability of advanced treatment options.
The Asia-Pacific region has the fastest-growing atopic eczema treatment market, valued at approximately a CAGR of around 12.6% in 2023. This growth is primarily driven by countries like China, Japan, and India, where there is a rising prevalence of atopic dermatitis, increasing healthcare expenditure, and improving healthcare infrastructure. China dominates the market due to its large population and growing healthcare sector. The market benefits from increasing awareness of skin diseases, rising disposable incomes, and the adoption of new treatment options.
In Latin America, the atopic eczema treatment market is experiencing steady growth, particularly in Brazil and Mexico. The growth in this region is driven by the increasing prevalence of atopic dermatitis, improving healthcare infrastructure, and rising healthcare awareness. Economic development and government initiatives to enhance healthcare access also contribute to market growth.
The atopic eczema treatment market in the Middle East and Africa is smaller compared to other regions but growing steadily. The market growth is driven by increasing healthcare expenditure, improving healthcare infrastructure, and a rising prevalence of skin diseases. Countries like Saudi Arabia, the UAE, and South Africa are key markets within this region. The demand for atopic eczema treatments is supported by growing awareness of dermatological conditions and the availability of advanced treatment options.
Atopic Eczema Treatment Market: List of Key Players
Some of the main competitors dominating the global atopic eczema treatment market include;
- AbbVie Inc.
- AnaptysBio, Inc.
- Astellas Pharma Inc.
- Bristol-Myers Squibb Company
- Dermira, Inc. (acquired by Eli Lilly and Company)
- Encore Dermatology, Inc.
- Galderma S.A.
- Incyte Corporation
- LEO Pharma A/S
- Medimetriks Pharmaceuticals, Inc.
- Medimmune LLC. (AstraZeneca)
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Sanofi
The global atopic eczema treatment market is segmented as follows:
By Drug Class Segment Analysis
- Biologics
- PDE-4 Inhibitors
- Calcineurin Inhibitors
- Corticosteroids
By Route of Administration Segment Analysis
- Injectable
- Topical
- Oral
By Application Segment Analysis
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
By Regional Segment Analysis
- North America
- The U.S.
- Canada
- Mexico
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Content
Industry Major Market Players
- AbbVie Inc.
- AnaptysBio, Inc.
- Astellas Pharma Inc.
- Bristol-Myers Squibb Company
- Dermira, Inc. (acquired by Eli Lilly and Company)
- Encore Dermatology, Inc.
- Galderma S.A.
- Incyte Corporation
- LEO Pharma A/S
- Medimetriks Pharmaceuticals, Inc.
- Medimmune LLC. (AstraZeneca)
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Sanofi
Copyright © 2023 - 2024, All Rights Reserved, Facts and Factors